FREE SHIPPING over $40
OVER 10000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Journal of immunological methods2016; 430; 56-60; doi: 10.1016/j.jim.2016.01.006

Optimizing selection of large animals for antibody production by screening immune response to standard vaccines.

Abstract: Antibodies made in large animals are integral to many biomedical research endeavors. Domesticated herd animals like goats, sheep, donkeys, horses and camelids all offer distinct advantages in antibody production. However, their cost of use is often prohibitive, especially where poor antigen response is commonplace; choosing a non-responsive animal can set a research program back or even prevent experiments from moving forward entirely. Over the course of production of antibodies from llamas, we found that some animals consistently produced a higher humoral antibody response than others, even to highly divergent antigens, as well as to their standard vaccines. Based on our initial data, we propose that these "high level responders" could be pre-selected by checking antibody titers against common vaccines given to domestic farm animals. Thus, time and money can be saved by reducing the chances of getting poor responding animals and minimizing the use of superfluous animals.
Copyright © 2016 Elsevier B.V. All rights reserved.
Get Full Text
Publication Date: 2016-01-09 PubMed ID: 26775851PubMed Central: PMC4769958DOI: 10.1016/j.jim.2016.01.006Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article
  • Research Support
  • N.I.H.
  • Extramural
  • Research Support
  • Non-U.S. Gov't

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

This research focused on improving the selection process for large animals used in the production of antibodies for biomedical research, with the goal of saving resources and improving efficiency in scientific research.

Overview of Animal Selection for Antibody Production

  • The study begins by acknowledging the importance of large animals like goats, sheep, donkeys, horses, and camelids, which are often used for producing antibodies for biomedical research.
  • However, the research also points out that these animals are expensive to use, and the cost becomes more prohibitive if the animals do not respond well to antigens – substances that trigger immune response.
  • One of the challenges in antibody production in these animals is that some animals may not respond well to a specific antigen, which means that the efforts to make these animals produce the needed antibodies may fail, thereby affecting the progress of research activities.

Study Findings

  • In this research, there was an observation made while producing antibodies from llamas that some animals consistently produced higher humoral (fluid-based) antibody responses than others, despite differences in the types of antigens introduced.
  • The same animals also had a high immune response to the standard vaccines they were given, which posed a potential solution to the previous problem – animals which responded well to their standard vaccines also responded well to other antigens.

Proposal for Optimized Animal Selection

  • This observation led the researchers to propose a new method to select animals for antibody production where they would pre-screen animals based on their antibody titers, which are measures of how much antibody an organism produces, against the common vaccines given to domestic farm animals.
  • If an animal has high antibody titers in response to a standard vaccine, it is likely that the animal will also have a high immune response to other antigens, making it a good candidate for antibody production.

Benefits of the Proposal

  • This approach can save time and money by reducing the risk of selecting an animal with poor response potential, thereby improving the efficiency of lab work.
  • It also minimizes the use of unnecessary animals in the research process, contributing to alleviation of ethical concerns in animal-based research.

Cite This Article

APA
Thompson MK, Fridy PC, Keegan S, Chait BT, Fenyö D, Rout MP. (2016). Optimizing selection of large animals for antibody production by screening immune response to standard vaccines. J Immunol Methods, 430, 56-60. https://doi.org/10.1016/j.jim.2016.01.006

Publication

Journal of immunological methods
ISSN: 1872-7905
NlmUniqueID: 1305440
Country: Netherlands
Language: English
Volume: 430
Pages: 56-60
PII: S0022-1759(16)30005-9

Researcher Affiliations

Thompson, Mary K
  • Laboratory of Cellular and Structural Biology, The Rockefeller University, New York, NY, USA.
Fridy, Peter C
  • Laboratory of Cellular and Structural Biology, The Rockefeller University, New York, NY, USA.
Keegan, Sarah
  • Center for Health Informatics and Bioinformatics, New York University School of Medicine, New York, NY, USA.
Chait, Brian T
  • Laboratory of Mass Spectrometry and Gaseous Ion Chemistry, The Rockefeller University, New York, NY, USA.
Fenyö, David
  • Center for Health Informatics and Bioinformatics, New York University School of Medicine, New York, NY, USA.
Rout, Michael P
  • Laboratory of Cellular and Structural Biology, The Rockefeller University, New York, NY, USA. Electronic address: rout@rockefeller.edu.

MeSH Terms

  • Animals
  • Antibodies, Viral / blood
  • Antibody Formation
  • Camelids, New World / immunology
  • Female
  • Green Fluorescent Proteins / immunology
  • Luminescent Proteins / immunology
  • Male
  • Rabies Vaccines / immunology
  • Rabies virus / immunology
  • Sheep
  • Vaccination / veterinary

Grant Funding

  • P41 GM103314 / NIGMS NIH HHS
  • P41 GM109824 / NIGMS NIH HHS

References

This article includes 23 references
  1. Appleyard G, Wilkie BN, Kennedy BW, Mallard BA. Antibody avidity in Yorkshire pigs of high and low immune response groups.. Vet Immunol Immunopathol 1992 Mar;31(3-4):229-40.
    pubmed: 1589953doi: 10.1016/0165-2427(92)90011-egoogle scholar: lookup
  2. Bishop RF, Cipriani E, Lund JS, Barnes GL, Hosking CS. Estimation of rotavirus immunoglobulin G antibodies in human serum samples by enzyme-linked immunosorbent assay: expression of results as units derived from a standard curve.. J Clin Microbiol 1984 Apr;19(4):447-52.
    pmc: PMC271092pubmed: 6325495doi: 10.1128/jcm.19.4.447-452.1984google scholar: lookup
  3. Coghill RD, Fell N, Creighton M, Brown G. The elimination of horse-serum specificity from antitoxins.. J Immunol 1940;39:207–222.
  4. Conti F, Abnave P, Ghigo E. Unconventional animal models: a booster for new advances in host-pathogen interactions.. Front Cell Infect Microbiol 2014;4:142.
    pmc: PMC4189411pubmed: 25340043doi: 10.3389/fcimb.2014.00142google scholar: lookup
  5. Eckersley AM, Petrovsky N, Kinne J, Wernery R, Wernery U. Improving the dromedary antibody response: The hunt for the ideal camel adjuvant.. J Camel Pract And Res 2011;18:35–46.
  6. Fridy PC, Li Y, Keegan S, Thompson MK, Nudelman I, Scheid JF, Oeffinger M, Nussenzweig MC, Fenyö D, Chait BT, Rout MP. A robust pipeline for rapid production of versatile nanobody repertoires.. Nat Methods 2014 Dec;11(12):1253-60.
    pmc: PMC4272012pubmed: 25362362doi: 10.1038/nmeth.3170google scholar: lookup
  7. Garvey JS, Cremer NE, Sussdorf DH, Campbell DH. Methods in immunology : a laboratory text for instruction and research.. .
  8. Hamers-Casterman C, Atarhouch T, Muyldermans S, Robinson G, Hamers C, Songa EB, Bendahman N, Hamers R. Naturally occurring antibodies devoid of light chains.. Nature 1993 Jun 3;363(6428):446-8.
    pubmed: 8502296doi: 10.1038/363446a0google scholar: lookup
  9. Hanly WC, Artwohl JE, Bennett BT. Review of Polyclonal Antibody Production Procedures in Mammals and Poultry.. ILAR J 1995;37(3):93-118.
    pubmed: 11528030doi: 10.1093/ilar.37.3.93google scholar: lookup
  10. Harmsen MM, De Haard HJ. Properties, production, and applications of camelid single-domain antibody fragments.. Appl Microbiol Biotechnol 2007 Nov;77(1):13-22.
    pmc: PMC2039825pubmed: 17704915doi: 10.1007/s00253-007-1142-2google scholar: lookup
  11. Hein WR, Griebel PJ. A road less travelled: large animal models in immunological research.. Nat Rev Immunol 2003 Jan;3(1):79-84.
    pubmed: 12511878doi: 10.1038/nri977google scholar: lookup
  12. Klarenbeek A, El Mazouari K, Desmyter A, Blanchetot C, Hultberg A, de Jonge N, Roovers RC, Cambillau C, Spinelli S, Del-Favero J, Verrips T, de Haard HJ, Achour I. Camelid Ig V genes reveal significant human homology not seen in therapeutic target genes, providing for a powerful therapeutic antibody platform.. MAbs 2015;7(4):693-706.
    pmc: PMC4622956pubmed: 26018625doi: 10.1080/19420862.2015.1046648google scholar: lookup
  13. Magnusson U, Bossé J, Mallard BA, Rosendal S, Wilkie BN. Antibody response to Actinobacillus pleuropneumoniae antigens after vaccination of pigs bred for high and low immune response.. Vaccine 1997 Jun;15(9):997-1000.
    pubmed: 9261946doi: 10.1016/s0264-410x(96)00294-0google scholar: lookup
  14. Mallard BA, Wilkie BN, Kennedy BW, Quinton M. Use of estimated breeding values in a selection index to breed Yorkshire pigs for high and low immune and innate resistance factors.. Animal Biotechnology 1992;3:257–280.
  15. Miura K, Orcutt AC, Muratova OV, Miller LH, Saul A, Long CA. Development and characterization of a standardized ELISA including a reference serum on each plate to detect antibodies induced by experimental malaria vaccines.. Vaccine 2008 Jan 10;26(2):193-200.
    pmc: PMC2253722pubmed: 18054414doi: 10.1016/j.vaccine.2007.10.064google scholar: lookup
  16. Muyldermans S. Nanobodies: natural single-domain antibodies.. Annu Rev Biochem 2013;82:775-97.
    pubmed: 23495938doi: 10.1146/annurev-biochem-063011-092449google scholar: lookup
  17. . Compendium of animal rabies prevention and control, 2011.. MMWR Recomm Rep 2011 Nov 4;60(RR-6):1-17.
    pubmed: 22052042
  18. Ovsyannikova IG, Dhiman N, Jacobson RM, Poland GA. Human leukocyte antigen polymorphisms: variable humoral immune responses to viral vaccines.. Expert Rev Vaccines 2006 Feb;5(1):33-43.
    pubmed: 16451106doi: 10.1586/14760584.5.1.33google scholar: lookup
  19. Poland GA, Kennedy RB, McKinney BA, Ovsyannikova IG, Lambert ND, Jacobson RM, Oberg AL. Vaccinomics, adversomics, and the immune response network theory: individualized vaccinology in the 21st century.. Semin Immunol 2013 Apr;25(2):89-103.
    pmc: PMC3752773pubmed: 23755893doi: 10.1016/j.smim.2013.04.007google scholar: lookup
  20. Stiles BG, Barth G, Barth H, Popoff MR. Clostridium perfringens epsilon toxin: a malevolent molecule for animals and man?. Toxins (Basel) 2013 Nov 12;5(11):2138-60.
    pmc: PMC3847718pubmed: 24284826doi: 10.3390/toxins5112138google scholar: lookup
  21. Tsang JS, Schwartzberg PL, Kotliarov Y, Biancotto A, Xie Z, Germain RN, Wang E, Olnes MJ, Narayanan M, Golding H, Moir S, Dickler HB, Perl S, Cheung F. Global analyses of human immune variation reveal baseline predictors of postvaccination responses.. Cell 2014 Apr 10;157(2):499-513.
    pmc: PMC4139290pubmed: 24725414doi: 10.1016/j.cell.2014.03.031google scholar: lookup
  22. Wagner KS, Stickings P, White JM, Neal S, Crowcroft NS, Sesardic D, Efstratiou A. A review of the international issues surrounding the availability and demand for diphtheria antitoxin for therapeutic use.. Vaccine 2009 Dec 10;28(1):14-20.
    pubmed: 19818425doi: 10.1016/j.vaccine.2009.09.094google scholar: lookup
  23. Wilde H, Thipkong P, Sitprija V, Chaiyabutr N. Heterologous antisera and antivenins are essential biologicals: perspectives on a worldwide crisis.. Ann Intern Med 1996 Aug 1;125(3):233-6.
    pubmed: 8686982doi: 10.7326/0003-4819-125-3-199608010-00012google scholar: lookup

Citations

This article has been cited 7 times.
  1. Cross FR, Fridy PC, Ketaren NE, Mast FD, Li S, Olivier JP, Pecani K, Chait BT, Aitchison JD, Rout MP. Expanding and improving nanobody repertoires using a yeast display method: Targeting SARS-CoV-2. J Biol Chem 2023 Mar;299(3):102954.
    doi: 10.1016/j.jbc.2023.102954pubmed: 36720309google scholar: lookup
  2. Mast FD, Fridy PC, Ketaren NE, Wang J, Jacobs EY, Olivier JP, Sanyal T, Molloy KR, Schmidt F, Rutkowska M, Weisblum Y, Rich LM, Vanderwall ER, Dambrauskas N, Vigdorovich V, Keegan S, Jiler JB, Stein ME, Olinares PDB, Herlands L, Hatziioannou T, Sather DN, Debley JS, Fenyö D, Sali A, Bieniasz PD, Aitchison JD, Chait BT, Rout MP. Highly synergistic combinations of nanobodies that target SARS-CoV-2 and are resistant to escape. Elife 2021 Dec 7;10.
    doi: 10.7554/eLife.73027pubmed: 34874007google scholar: lookup
  3. Flores J, Cancino JC, Chavez-Galan L. Lipoarabinomannan as a Point-of-Care Assay for Diagnosis of Tuberculosis: How Far Are We to Use It?. Front Microbiol 2021;12:638047.
    doi: 10.3389/fmicb.2021.638047pubmed: 33935997google scholar: lookup
  4. Mast FD, Fridy PC, Ketaren NE, Wang J, Jacobs EY, Olivier JP, Sanyal T, Molloy KR, Schmidt F, Rutkowska M, Weisblum Y, Rich LM, Vanderwall ER, Dambrauskas N, Vigdorovich V, Keegan S, Jiler JB, Stein ME, Olinares PDB, Hatziioannou T, Sather DN, Debley JS, Fenyö D, Sali A, Bieniasz PD, Aitchison JD, Chait BT, Rout MP. Nanobody Repertoires for Exposing Vulnerabilities of SARS-CoV-2. bioRxiv 2021 Apr 10;.
    doi: 10.1101/2021.04.08.438911pubmed: 33851164google scholar: lookup
  5. Figueroa C, Veloso P, Espin L, Dixon B, Torrealba D, Elalfy IS, Afonso JM, Soto C, Conejeros P, Gallardo JA. Host genetic variation explains reduced protection of commercial vaccines against Piscirickettsia salmonis in Atlantic salmon. Sci Rep 2020 Oct 26;10(1):18252.
    doi: 10.1038/s41598-020-70847-9pubmed: 33106499google scholar: lookup
  6. Khan SU, Wuryastuty H, Wibowo MH, Wasito R, Aji D, Sarmin S. Development of high-titer polyclonal antisera targeting a local bovine viral diarrhea virus-1a strain: A preliminary study from Indonesia. Vet World 2025 Oct;18(10):3208-3217.
    doi: 10.14202/vetworld.2025.3208-3217pubmed: 41333736google scholar: lookup
  7. Zafarmand-Samarin M, Nazarian S, Aghaie SM, Sadeghi D, Samiei-Abianeh H, Felegary A. Therapeutic efficacy of SipD/LptD-specific IgY entrapped in alginate nanoparticles against Salmonella Typhimurium infection. Heliyon 2024 Nov 15;10(21):e39650.
    doi: 10.1016/j.heliyon.2024.e39650pubmed: 39524789google scholar: lookup
Subscribe to our newsletter
Join 99,824 horse owners like you who receive our email updates on horse health and nutrition.